Maintenance therapy versus episodic therapy with infliximab for Crohn's disease

被引：0

作者：

Subrata Ghosh

机构：

[1] Professor of Gastroenterology,

[2] Imperial College,undefined

来源：

Nature Clinical Practice Gastroenterology & Hepatology | 2004年 / 1卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：80 / 81

页数：1

共 5 条

[1]

Sandborn WJ(2003)Preventing antibodies to infliximab in patients with Crohn's disease: optimize, not immunize Gastroenterology 124 1140-1145

[2]

Maini R(1999)Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT study group Lancet 354 1932-1939

[3]

Rutgeerts P(2004)Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease Gastroenterology 126 402-413

[4]

Baert F(2003)Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 601-608

[5]

Farrell RJ(2003)Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial Gastroenterology 124 917-924

← 1 →